Michael A Marletta

US Patent:

8404631, Mar 26, 2013

Filed:

May 21, 2007

Appl. No.:

12/302002

Inventors:

Stephen P. L. Cary - San Mateo CA, US
Elizabeth M. Boon - Stony Brook NY, US
Emily Weinert - Berkeley CA, US
Jonathan A. Winger - Oakland CA, US
Michael A. Marletta - Berkeley CA, US

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

C07K 14/00

US Classification:

514 1, 530350

Abstract:

H-NOX proteins are mutated to exhibit improved or optimal kinetic and thermodynamic properties for blood gas Odelivery. The engineered H-NOX proteins comprise mutations that impart altered Oor NO ligand-binding relative to the corresponding wild-type H-NOX domain, and are operative as physiologically compatible mammalian blood Ogas carriers. The invention also provides pharmaceutical compositions, kits, and methods that use wild-type or mutant H-NOX proteins for the treatment of any condition for which delivery of Ois beneficial.

US Patent:

8404632, Mar 26, 2013

Filed:

May 21, 2007

Appl. No.:

12/302004

Inventors:

Stephen P. L. Cary - San Mateo CA, US
Elizabeth M. Boon - Stony Brook NY, US
Jonathan A. Winger - Oakland CA, US
Michael A. Marletta - Berkeley CA, US

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

C07K 14/00

US Classification:

514 1, 530350

Abstract:

H-NOX proteins are mutated to exhibit improved or optimal kinetic and thermodynamic properties for blood gas NO delivery. The engineered H-NOX proteins comprise mutations that impart altered NO or Oligand-binding relative to the corresponding wild-type H-NOX domain, and are operative as physiologically compatible mammalian blood NO gas carriers. The invention also provides pharmaceutical compositions, kits, and methods that use wild-type or mutant H-NOX proteins for the treatment of any condition for which delivery of NO is beneficial.

US Patent:

8569022, Oct 29, 2013

Filed:

Jun 23, 2011

Appl. No.:

13/813153

Inventors:

James H. Doudna Cate - Berkeley CA, US
Michael A. Marletta - Berkeley CA, US

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

C12P 7/58

US Classification:

435137

Abstract:

The present disclosure relates to hydrolysis of hexose-δ-lactones by use of an extracellular aldonolactonase. In particular the present disclosure relates to compositions including a extracellular aldonolactonase and methods of use thereof.

US Patent:

20110243849, Oct 6, 2011

Filed:

Mar 31, 2011

Appl. No.:

13/077686

Inventors:

Michael A. Marletta - Berkeley CA, US
Michael B. Winter - Berkeley CA, US
Emily J. McLaurin - Seattle MA, US
Steven Y. Reece - Cambridge MA, US
Charles Olea, JR. - San Diego CA, US
Daniel G. Nocera - Winchester MA, US

International Classification:

A61K 49/00
C07K 14/795
C07K 14/805
C07K 14/80
C12N 9/96
C12P 21/00
G01N 21/75
C12N 13/00
C07K 19/00
B82Y 15/00

US Classification:

424 91, 530400, 530385, 530401, 5303911, 435188, 435 691, 435 71, 4351731, 435 696, 977774, 977920

Abstract:

The present disclosure provides photoactive polypeptides. A subject photoactive polypeptide is useful in a variety of applications, which are also provided.

US Patent:

20110245326, Oct 6, 2011

Filed:

Apr 6, 2010

Appl. No.:

12/755121

Inventors:

Brian J. Belmont - Cambridge MA, US
Stephen J. Goldfless - Cambridge MA, US
Michael A. Marletta - Berkeley CA, US
Jacquin C. Niles - Arlington MA, US

International Classification:

A61K 31/713
C07H 21/02
C07K 14/00
C12P 21/00
A61P 43/00
B65D 71/00

US Classification:

514 44 R, 536 231, 530350, 435 691, 206223

Abstract:

In vitro SELEX has been used to discover high affinity RNA aptamers interacting with the tetracycline repressor protein in a tetracycline-dependent manner. Using in silico RNA folding predictions to guide the design of both aptamer truncations and mutants, minimized tetracycline repressor protein high affinity binding aptamers have been defined. Using one such aptamer, inducible post-transcriptional regulation in vivo has been demonstrated that is predicated on a direct interaction between a tetracycline repressor protein and a RNA aptamer element. These aptamer components can be integrated in any organism to inducibly regulate RNA translation of a gene of interest.

US Patent:

20130288970, Oct 31, 2013

Filed:

Feb 20, 2013

Appl. No.:

13/772281

Inventors:

The Regents Of The University Of California - , US
Elizabeth M. BOON - Stony Brook NY, US
Emily WEINERT - Berkeley CA, US
Jonathan A. WINGER - San Francisco CA, US
Michael A. MARLETTA - Berkeley CA, US

Assignee:

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA - OAKLAND CA

International Classification:

C07K 14/47

US Classification:

514 134, 530350, 536 235, 4353201, 435348, 435419, 4352542, 4352523, 435325, 435 691

Abstract:

H-NOX proteins are mutated to exhibit improved or optimal kinetic and thermodynamic properties for blood gas Odelivery. The engineered H-NOX proteins comprise mutations that impart altered Oor NO ligand-binding relative to the corresponding wild-type H-NOX domain, and are operative as physiologically compatible mammalian blood Ogas carriers. The invention also provides pharmaceutical compositions, kits, and methods that use wild-type or mutant H-NOX proteins for the treatment of any condition for which delivery of Ois beneficial.

US Patent:

20130289252, Oct 31, 2013

Filed:

Feb 20, 2013

Appl. No.:

13/772283

Inventors:

Elizabeth M. BOON - Stony Brook NY, US
Jonathan A. WINGER - San Francisco CA, US
Michael A. MARLETTA - Berkeley CA, US

International Classification:

C07K 14/47

US Classification:

530400, 536 235, 4353201, 435348, 435 691, 435419, 4352542, 4352523, 435325

Abstract:

H-NOX proteins are mutated to exhibit improved or optimal kinetic and thermodynamic properties for blood gas NO delivery. The engineered H-NOX proteins comprise mutations that impart altered NO or Oligand-binding relative to the corresponding wild-type H-NOX domain, and are operative as physiologically compatible mammalian blood NO gas carriers. The invention also provides pharmaceutical compositions, kits, and methods that use wild-type or mutant H-NOX proteins for the treatment of any condition for which delivery of NO is beneficial.

US Patent:

20140038245, Feb 6, 2014

Filed:

Oct 10, 2013

Appl. No.:

14/051402

Inventors:

James H. DOUDNA CATE - Berkeley CA, US
Michael A. MARLETTA - Berkeley CA, US

Assignee:

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA - Oakland CA

International Classification:

C12P 19/02

US Classification:

435105

Abstract:

The present disclosure relates to hydrolysis of hexose-δ-lactones by use of an extracellular aldonolactonase. In particular the present disclosure relates to compositions including a extracellular aldonolactonase and methods of use thereof.